12/12
05:32 pm
avxl
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease [Yahoo! Finance]
Low
Report
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease [Yahoo! Finance]
12/12
04:05 pm
avxl
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
Low
Report
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
12/11
10:00 am
avxl
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Neutral
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
12/10
09:50 am
avxl
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
Medium
Report
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
12/3
07:39 pm
avxl
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
Medium
Report
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
12/2
10:00 pm
avxl
Anavex Life Sciences: Negative CHMP Decision Does Not Bode Well For Future Approval For Alzheimer's [Seeking Alpha]
High
Report
Anavex Life Sciences: Negative CHMP Decision Does Not Bode Well For Future Approval For Alzheimer's [Seeking Alpha]
12/2
11:47 am
avxl
Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL) [Yahoo! Finance]
Low
Report
Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL) [Yahoo! Finance]
11/28
07:02 am
avxl
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/26
02:01 pm
avxl
Anavex Life Sciences (NASDAQ:AVXL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Anavex Life Sciences (NASDAQ:AVXL) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
12:56 pm
avxl
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
Medium
Report
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
11/26
07:53 am
avxl
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference [Yahoo! Finance]
Medium
Report
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference [Yahoo! Finance]
11/26
07:30 am
avxl
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
High
Report
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
11/25
04:20 pm
avxl
Anavex Life Sciences Corp (AVXL) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]
High
Report
Anavex Life Sciences Corp (AVXL) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]
11/25
07:58 am
avxl
Anavex Life Sciences: Fiscal Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Anavex Life Sciences: Fiscal Q4 Earnings Snapshot [Yahoo! Finance]
11/25
07:30 am
avxl
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
High
Report
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
11/19
10:01 am
avxl
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
11/19
08:07 am
avxl
Anavex Life Sciences (NASDAQ:AVXL) had its price target lowered by analysts at HC Wainwright from $42.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
Anavex Life Sciences (NASDAQ:AVXL) had its price target lowered by analysts at HC Wainwright from $42.00 to $20.00. They now have a "buy" rating on the stock.
11/19
07:30 am
avxl
Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference
Low
Report
Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference
11/18
07:56 pm
avxl
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
11/18
07:30 am
avxl
Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025
Low
Report
Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025
11/17
04:43 am
avxl
Why Anavex Life Sciences (AVXL) Is Down 43.8% After EMA Setback for Lead Alzheimer's Drug [Yahoo! Finance]
Neutral
Report
Why Anavex Life Sciences (AVXL) Is Down 43.8% After EMA Setback for Lead Alzheimer's Drug [Yahoo! Finance]
11/12
08:50 am
avxl
Anavex Nears Alzheimer's Decision With Limited Pipeline Offsets And ATM Overhang [Seeking Alpha]
Low
Report
Anavex Nears Alzheimer's Decision With Limited Pipeline Offsets And ATM Overhang [Seeking Alpha]
10/29
08:44 am
avxl
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $46.00 price target on the stock.
Low
Report
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $46.00 price target on the stock.
10/29
07:30 am
avxl
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group
Medium
Report
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group
10/24
08:13 am
avxl
Anavex Life Sciences (NASDAQ:AVXL) had its "hold" rating reaffirmed by analysts at Jones Trading.
Low
Report
Anavex Life Sciences (NASDAQ:AVXL) had its "hold" rating reaffirmed by analysts at Jones Trading.